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Aim. Serine/threonine protein phosphatase 5 (PP5) is a unique member of serine/threonine phosphatase family,
comprises a regulatory tetratricopeptide repeat (TPR) domain and regulates many cell signaling pathways.
Here, we describe the development of a PP5 specific monoclonal antibody (mAb) and characterize its suitability
for Western blotting and immunoprecipitation.Methods. Hybridoma technology has been used for monoclonal
antibody generation. Immunization was carried out with recombinant mouse PP5 expressed in Escherichia coli
as a GST-tagged fusion protein. Results. mAb against PP5 has been generated. Conclusions. Generated mAb
specifically recognizes recombinant and endogenous mouse and rat PP5 and is suitable for Western blotting and
immunoprecipitation. This mAb will be useful tool for investigations of PP5 physiological role.
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Introduction. Serine/threonine protein phosphatase 5
(PP5) is a member of the PPP family of serine/threoni-
ne phosphatases, which includes PP1, PP2A, PP2B,
PP2C, PP4, PP6 and PP7 [1]. PP5 possesses four N-ter-
minal tetratricopeptide repeat (TPR) domains [2],
which are implicated in protein-protein interactions [3–
8]. The catalytic activity of PP5 was reported to be inhi-
bited in vitro by an okadaic acid/cantharidin/microcys-
tin and activated by arachidonic acid [2, 9]. Although,
PP5 is highly conserved among species the biological
and pathological role of PP5 is not clear yet. It has been
shown that PP5 is ubiquitously expressed in normal
tissues, and high PP5 protein expression level has been
observed in different types of human cancer [10–15].
PP5 exists in cell in different multiprotein complexes
and has been reported to be involved in the regulation
of various biological processes such as glucocorticoid
receptor activity [16–18], apoptosis [19–21], cell res-
ponse to UV light or ionizing radiation [22, 23], geno-
mic stress response [19–21, 24–26]; additionally, PP5
appears to play an important role in balancing the cel-
lular responses to the transforming growth factor-
(TGF-) signal [27].
Recently we have identified PP5 as a new binding
partner for a TSC2, a component of tuberous sclerosis
complex TSC1/2 [28–30]. TSC1/2 complex serves as a
point of integration between growth-stimulatory and
growth-suppressive signaling upstream of mTOR in
PI3Ê/Akt/mTOR signaling pathway. The last one is imp-
licated in signal transduction from mitogenic growth
factors, nutrients, cellular energy levels and stress con-
ditions to stimulate protein synthesis and cell growth
[31, 32]. So far, very little is known about the molecu-
lar mechanisms of TSC2 dephosphorylation. There-
fore, we hypothesized that the inter action with PP5
may control the phosphorylation status of TSC2.
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To analyze the specificity of interactions between
TSC2 and PP5 we developed monoclonal antibody
(mAb), which recognizes PP5. Recombinant GST-
tagged PP5 protein (GST-PP5) was used for mice im-
munization and hybridoma screening procedure. Here,
we report that developed mAb specifically recognizes
recombinant and endogenous PP5 in Western blotting
and immunoprecipitation assay. This mAb could be a
useful tool in study of PP5-mediated signal transduc-
tion pathways.
Materials and methods. Purification of GST-PP5
fusion protein. The bacterial expression system has
been used for production of mouse full length GST-
PP5 fusion protein. Generated plasmid pET42a/PP5
was transformed into Escherichia coli BL21 (lysE) and
the expression of GST-PP5 fused protein was induced
with 1 mM isopropyl--D(2)-thiogalactopyranoside
(IPTG) for 3 h at 28 °C. Affinity purification of GST-
PP5 was carried out under native conditions using Glu-
tathione-Sepharose («Amersham», UK) as recommen-
ded by manufactures. The quality of the purified re-
combinant protein was tested by sodium dodecyl sul-
fate-polyacrylamide gel electrophoresis (SDS-PAGE).
Production of hybridomas. Briefly, generation of
mAb has been performed as described earlier [34].
Female BALB/c mice (6–8 weeks old) were immu-
nized with 20 µg of recombinant GST-PP5 fusion pro-
tein in complete Freund’s adjuvant by intraperitoneal
injections (i. p.) every two weeks. When the titer of an-
ti-PP5 antibody in the serum of immunized mouse rea-
ched 10–5, the hybridomas production was performed
according to a standard protocol [33]. Immunized mice
were boosted with 20 µg of antigen in phosphate-buf-
fered saline (PBS) by i. p. injection. Three days later,
spleenocytes from immunized mouse and SP2/0 mye-
loma cells were fused in the presence of PEG (MW
2000, «Merck», Germany). SP2/0 myeloma cells were
cultured in RPMI 1640 medium containing 20 % fetal
calf serum (FCS). Primary screening of hybridoma su-
pernatants was performed 7 days later using ELISA.
Isolated positive clones were subcloned by limiting di-
lution method [33].
ELISA assay. Polystyrene 96-well plates were loa-
ded with GST-PP5 in the concentration 0.3 µg/well for
2 h at 37 °C. The plates were washed three times with
PBS containing 0.1 % Tween-20 («Sigma», USA). For
blocking of non-specific binding plates were incubated
with 2 % bovine serum albumin (BSA) in PBS (pH 7.4)
overnight at 4 °C (200 µl/well). Subsequently, the pla-
tes were loaded with 100 µl/well aliquots of hybri
doma supernatant and incubated for 1 h at 37 °C, se-
rum from immunized mouse was used as positive
control. After three times washing, 100 µl of horsera-
dish peroxidase (HRP)-conjugated goat anti-mouse IgG
antibodies (1:5000 v/v, «Promega», USA) were added
to each well following the incubation at 37 °C for 1 h.
Plates were washed three times and substrate solution
(0.02 % H2O2, 0.5 mg/ml 2.2'-azino-bis(3-ethylbenzo-
thiazoline-6-sulfonic acid) sodium salt («Sigma») in
0.1 M citrate-phosphate buffer (pH 5.8)) was added to
each well. After 15-min incubation at 37 °C, the absor-
bance of the each well was determined at 490 nm in an
ELISA reader.
Hybridoma selection in Western blot analysis. Bac-
terially expressed GST-PP5 recombinant protein was
boiled in sample buffer, resolved by a 10 % SDS-PAGE
and electrotransferred to Immobilon-P membrane («Mil-
lipore», USA). The membrane was divided into strips,
blocked by 0.5 % gelatin in PBS for 1 h at room tem-
perature (RT) followed by a single wash with PBS con-
taining 0.1 % Tween-20. Strips were incubated with
either PBS, post-immune serum (1:1000), hybridoma
supernatants from clones, or cell culture media alone
for 4 h at RT. After three times washing, a HRP-
conjugated goat anti-mouse lgG («Promega») was ad-
ded to the strips and incubated for 1 h at RT. Strips were
washed three times, and developed by ECL Western
blotting reagent («Amersham», Sweden).
Purification of mAb. For monoclonal antibody asci-
tes fluid production BALB/c mice were injected with
0.5 ml of pristane and 7–10 days later inoculated with
510
6 of hybridoma cells [34]. The ascitic fluid was col-
lected after 7–10 days. The fraction of immunoglobu-
lins was precipitated from ascitic fluid with 50 % am-
monium sulphate, dialyzed overnight against PBS, pH
7.4 and purified by affinity chromatography using Pro-
tein A-Sepharose CL-4B («Amersham», Sweden). The
IgG fractions were pulled together and dialyzed against
PBS. The aliquots of purified antibodies were stored at
–70 °C.
Production of polyclonal serum. Polyclonal serum
has been collected from an immunized mouse by tail
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bleed before the hybridomas production was perfor-
med. Collected blood was incubated at 37 °C for 1 h
then transferred to 4 °C for 2 h, and after that spinned
down at 1500 rpm for 15 min at 4 °C. Serum was remo-
ved from cell pellet avoiding the packed one, diluted
with equal volume of glycerol and stored at – 20 °C.
Cell lines. TSC2+/+ p53–/– and TSC2–/– p53–/– MEFs
(mouse embryonic fibroblast), HEK293 (human emb-
ryonal kidney), MCF-7 (human breast adenocarci-
noma), CHO (Chinese hamster ovary cells) and HeLa
(human cervical cancer cells) were grown in DMEM
medium supplemented with 10 % (v/v) FCS and 2 mM
L-glutamine. Sp2/0 (murine myeloma) cells were cul-
tivated in RPMI-1640 medium supplemented with 10 %
(v/v) FCS and 2 mM L-glutamine.
Immunoblotting of cell lysates and organ extracts.
TSC2+/+ p53–/– MEFs, TSC2–/– p53–/– MEFs and HEK293
cell lines and both mouse and rat kidney, liver, spleen,
lung and brain extracts were lysed with lysis buffer
(50 mM Tris-HCI, pH 7.5, 150 mM NaCl, 1 % NP40,
50 mM NaF, 2 mM EDTA, 10 mM Na4P2O7) containing
the protease inhibitors cocktail («Roche Molecular Di-
agnostics», France) and spinned down at 10000 rpm for
10 min. Protein concentration in supernatant was esti-
mated by BCA assay («Pierce», USA), and equal
amounts of protein (50 µg) were resolved in SDS-
PAGE. Gels were transferred to polyvinylidene difluo-
ride (PVDF) membrane («Millipore»). The membrane
was blocked with 0.5 % gelatine in PBS containing
0.05 % Tween-20 (PBST) for 1 h at RT and incubated
overnight (o/n) with different dilutions of selected hyb-
ridoma supernatants at 4 °C. After washing with PBST,
membrane was stained with HRP-conjugated goat anti-
mouse lgG («Promega») during 1 h at RT. As a loading
control, mouse anti-actin antibody was used («Sig-
ma»). Western blot membranes were developed ECL
Western blotting reagent («Amersham», Sweden).
Immunoprecipitation. Hybridoma supernatants from
selected clones were incubated with 25 µl of 50 % sus-
pension of Protein A-Sepharose CL-4B («Amersham»,
Sweden) for 2 h at 4 °C. Then, beads were washed three
times in lysis buffer above and the lysates (500 µg of
protein) from cell lines TSC2+/+ p53–/– MEFs cells, HEK
293, HeLa, CHO, MCF7, rat brain extract were added.
After incubation o/n at 4 °C, beads were washed four
times with 1 ml of lysis buffer. Immune complexes we-
re removed from beads by boiling in Laemmli sample
buffer and separated by SDS-PAGE. Resolved proteins
were visualized by Coomassie staining or transferred
onto PVDF membrane for immunoblotting.
Results and discussion. Recent progress toward
understanding the mechanism of control on cell growth
indicates that the tuberous sclerosis complex TSC1/2
as tumor suppressor an upstream negative regulator of
mTOR activity. However, the regulation of tumor sup-
pression by TSC1 and TSC2 is not well understood.
We were interested in the elucidation of molecular me-
chanisms, which regulated TSC1/2 function in cellular
response to various extracellular stimuli. In the pre-
vious study, by the yeast two-hybrid screening we iden-
tified already known and novel binding partners for
TSC1 and TSC2 including Ser/Thr protein phosphatase
5 designated PP5 [28]. To analyze the specificity of in-
teractions between TSC2 and PP5 and to explore a po-
tential effect of PP5 on TSC2 phosphorylation status we
developed monoclonal antibody, which would specifi-
cally recognize PP5 in vivo.
Production and characterization of recombinant PP5
protein. We used the bacterial expression system to pro-
duce recombinant PP5 for mouse immunization and
hybridoma clone screening. The full length of mouse
PP5 was amplified by PCR and cloned into pET42a
vector in frame with the GST-tag sequence to facilitate
purification of recombinant protein. GST-PP5 was high-
ly expressed upon IPTG induction and shown to be so-
luble under native conditions (Fig. 1, A). For GST-PP5
fusion protein purification Glutathione-Sepharose affi-
nity chromatography was used (Fig. 1, B).
Hybridoma production and isolation of positive
clones. BALB/c mice were immunized with 20 µg of
purified GST-PP5 fusion protein in complete Freund’s
adjuvant every two weeks. Animals developed strong
immune response to the antigen, and the titer of speci-
fic antibody reached 10–5 in all immune sera after the
third immunization. Immune spleen cells were fused
with the myeloma cells Sp2/0 using PEG. After fusion
cells were incubated in RPMI medium containing anti-
biotics, 20 % fetal bovine serum, and hypoxanthine/
aminopterin/thymidine (HAT) as a selective agent. Ten
days later the first ELISA screening was carried out
using GST-PP5 fusion protein to coat ELISA plate. We
selected 14 positive hybridoma clones in the first round
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of screening. For selected clones a second ELISA scree-
ning was performed three days later and confirmed the
GST-PP5 specificity for 4 clones. Selected clones were
further subcloned twice using limiting dilution method.
Testing the specificity of selected clones in Western
blotting. Supernatants from four positive clones were
then tested by Western blotting using GST-PP5 pro-
tein. RPMI medium with 10 % FBS was used as a ne-
gative control. The serum collected from GST-PP5 im-
munized mouse was used as positive control. The obtai-
ned results clearly indicate that only one mAB, which
designated as A4/1, recognizes a protein at the level cor-
responding to GST-PP5 (Fig. 2).
Produced antibodies recognize endogenous PP5. To
determine whether the selected A4/1 mAb can recogni-
ze endogenous PP5, we tested their specificity in Wes-
tern blotting and immunoprecipitation assay using cell
lysates from different cell lines and organ extracts from
mouse and rat. For these purposes 50 µg of cell lysates
from TSC2+/+ p53–/– MEFs, TSC2–/– p53–/– MEFs, HEK
293, HeLa cell lines and organ extracts from mouse and
rat brain, kidney, liver, spleen, and lung were analyzed
in Western blot with A4/1 mAb. We found that mAb
A4/1 recognizes a protein of approximately 58 kDa in
TSC2+/+ p53–/– MEFs and TSC2–/– p53–/– MEFs but not
in HEK293 cell lines (Fig. 3, A). Moreover, we also
found that A4/1 mAb recognizes specifically endoge-
nous PP5 in immunoblot analysis of mouse and rat pro-
tein extracts from brain, kidney, liver, spleen and lung
(Fig. 3, B).
Then, we tested the ability of selected mAb to im-
munoprecipitate endogenouse PP5. In this assay, we
used protein extracts from rat brain, TSC2+/+ p53–/–
MEFs cells, HEK 293, HeLa, CHO, MCF7 cell lines
and IgGs from selected clone A4/1. Immune comple-
xes were resolved by SDS-PAGE and immunoblotted
with A4/1 mAb. The Protein A-Sepharose pre-incuba-
ted with lysate from TSC2+/+ p53–/– MEFs alone served
as a negative control.
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Fig. 1. Analysis of expression and affinity purification of recombinant GST-PP5 by SDS-PAGE: A – expression of GST-PP5 in BL21 pLysE cells
was induced by IPTG (harvested cells were lysed in lysis buffer and centrifuged at 13 000 rpm for 20 min; total cell lysates and the supernatants
from the IPTG induced and non-induced cells were separated by SDS-PAGE and Coomassie stained); B – affinity purification of GST-PP5 protein
on GST-sepharose under native conditions (the GST-PP5 expressing cells were incubated with the GST-sepharose as described in Material and me-
thods; after extensive washing, bound proteins were eluted in buffer containing 250 mM imidazole; obtained fractions were resolved by SDS-
PAGE and Coomassie stained); lane 1 – total lysate; lane 2 – lysate before GST-seph. binding; lane 3 – lysate after GST-seph. binding; lane 4 –
BSA; lane 5 – Protein Marker; lane 6–9 – elution 1–4, respectively; lane 10 – blank; lane 11 – GST-sepharose after elution. The position of
recombinant GST-PP5 is indicated by arrows
B9/3 C11/3 D3/7 A4/1
10 %
FBS
Immune
serum
Fig. 2. Western-blot analysis of hybridoma supernatants from different
clones with recombinant GST-PP5. Recombinant GST-PP5 was sepa-
rated in numerous lanes by SDS-PAGE and transferred to PVDF memb-
rane. The strips of membranes, corresponding to one lane were immuno-
blotted with hybridoma media from PP5 positive supernatants. Anti-
PP5 polyclonal serum and 10 % fetal bovine serum (FBS) were used as
positive and negative control, respectively. The position of GST-PP5
protein is indicated by arrows
We found that selected mAb was able to immunopre-
cipitate specifically PP5 from TSC2+/+ p53–/– MEFs and
rat brain extract (Fig. 4). However, despite PP5 is highly
conserved among species, generated mAb and polyclo-
nal serum (data not shown) didn’t recognize endoge-
nous PP5 in human (HEK293, HeLa, MCF7) or hams-
ter cells (CHO) neither under Western-blot analysis nor
immunoprecipitation assay (Fig. 3, 4). One possible ex-
planation is that antigen’s epitope for mAb A4/1 may
contain some non-homologous amino acids.
Taken together, this study describes the production
of monoclonal antibody, which recognizes mouse and
rat PP5. Generated mAb could be suitable for various
immunoassays, including ELISA, Western blotting
and immunoprecipitation. This mAb could be a useful
tool in study of PP5-mediated signaling under different
pathophysiological condition.
Acknowledgements. This work was particularly
supported by state Fund for fundamental researches,
Grant N F46/457-2011 and the President of Ukraine for
young scientists, project N GP/F36/095 on «Investiga-
tion of molecular mechanisms of regulation of TSC2 tu-
mor supressor activity».
Î. Ì. Ìàëàí÷óê, Ã. Â. Îâ÷àðåíêî, ². Î. Òèõîíêîâà, Î. Ñ. Õîìà,
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Îòðèìàííÿ ìîíîêëîíàëüíèõ àíòèò³ë äî ïðîòå¿íôîñôàòàçè 5
Ðåçþìå
Ìåòà. Ñåðèí-òðåîí³íîâà ïðîòå¿íôîñôàòàçà 5 (PP5) º óí³êàëü-
íèì ÷ëåíîì ðîäèíè ñåðèí-òðåîí³íîâèõ ïðîòå¿íôîñôàòàç, îñê³ëü-
êè ì³ñòèòü ðåãóëÿòîðí³ òåòðàòðèêîïåïòèäí³ ïîâòîðè (TPR).
PP5 áåðå àêòèâíó ó÷àñòü ó ïðîöåñàõ ñèãíàëüíî¿ òðàíñäóêö³¿. Îïè-
ñàíî ïðîöåäóðó îòðèìàííÿ ìîíîêëîíàëüíèõ àíòèò³ë, ñïåöèô³÷-
íèõ äî PP5, à òàêîæ îñîáëèâîñò³ ¿õíüîãî âèêîðèñòàííÿ ó Âåñ-
òåðí-áëîò àíàë³ç³ òà ³ìóíîïðåöèï³òàö³¿. Ìåòîäè. Ã³áðèäîìíó
òåõíîëîã³þ çàñòîñîâàíî äëÿ îòðèìàííÿ ìîíîêëîíàëüíèõ àíòè-
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Fig. 3. Western-blot analysis of monoclonal antibody A4/1 using cell lines and tissues: A – endogenous PP5 is specifically recognized by A4/1
mAb in Western blotting of TSC2
+/+
p53
–/–
MEFs and TSC2
–/–
p53
–/–
MEFs cell lines (total cell lysates (50 µg) were separated by SDS-PAGE and
immunoblotted with A4/1 mAb); B – endogenous PP5 is specifically recognized by A4/1 mAb in Western blotting of rat (right) and mouse (left)
extracts of organs (total organ extracts (50 µg) were separated by SDS-PAGE and immunoblotted with A4/1 mAb)
B
IgGH
WB:
A4/1 Mab
PP5
A
4
/1
M
a
b
T
S
C
2
+
/+
M
E
F
s
T
S
C
2
+
/+
M
E
F
s
M
C
F
7
C
H
O
H
eL
a
H
E
K
2
9
3
R
a
t
B
ra
in
A
WB:
A4/1 Mab
WB:
ànti-actin
T
S
C
2
+
/+
M
E
F
s
M
C
F
7
C
H
O
H
eL
a
H
E
K
2
9
3
R
a
t
B
ra
in
PP5
Actin
Fig. 4. Application of monoclonal antibody A4/1 in immunoprecipitation assay: A – the pattern of expression of PP5 in supernatants (50 µg) from
TSC2
+/+
p53
–/–
MEFs cells, HEK293, HeLa, CHO, MCF7, and extract of rat brain (50 µg) were analysed in Western blotting; B – cell lysates from
TSC2
+/+
p53
–/–
MEFs cells, HEK293, HeLa, CHO, MCF7 and extract of rat brain (500 µg) were incubated with Protein A-Sepharose containing
IgGs from A4/1 mAb. After extensive washing of beads with cell lysis buffer, specifically associated proteins were resolved by SDS-PAGE and
immunoblotted with A4/1 mAb. Lanes A4/1 Mab and TSC2
+/+
MEFs serves as positive and negative controles, respectively.
ò³ë. ²ìóí³çàö³þ ïðîâîäèëè ðåêîìá³íàíòíèì çëèòèì á³ëêîì GST-
òàã, ñèíòåçîâàíèì ó áàêòåð³éí³é ñèñòåì³. Ðåçóëüòàòè. Îäåðæà-
íî ñïåöèô³÷í³ ìîíîêëîíàëüí³ àíòèò³ëà ïðîòè ÐÐ5. Âèñíîâêè.
Ìîíîêëîíàëüí³ àíòèò³ëà ñïåöèô³÷íî ðîçï³çíàþòü ðåêîìá³íàíò-
íó òà åíäîãåííó PP5 ó Âåñòåðí-áëîò àíàëèç³ òà ³ìóíîïðåöèï³òà-
ö³¿. Âîíè ìîæóòü ñòàòè íåîáõ³äíèì ³íñòðóìåíòîì ïðè äîñë³ä-
æåíí³ ô³ç³îëîã³÷íî¿ ðîë³ PP5.
Êëþ÷îâ³ ñëîâà: ïðîòå¿íôîñôàòàçà 5, ã³áðèäîìíà òåõíîëîã³ÿ,
ìîíîêëîíàëüí³ àíòèò³ëà.
Î. Í. Ìàëàí÷óê, Ã. Â. Îâ÷àðåíêî, È. À. Òèõîíêîâà, À. Ñ. Õîìà,
Ó. À. ×îðíà, Ì. Þ. Ðèáàê, Ñ. Ñ. Ïàëü÷åâñêèé
Ïîëó÷åíèå ìîíîêëîíàëüíûõ àíòèòåë ê ïðîòåèíôîñôàòàçå 5
Ðåçþìå
Öåëü. Ñåðèí-òðåîíèíîâàÿ ïðîòåèíôîñôàòàçà 5 (PP5) ÿâëÿåòñÿ
óíèêàëüíûì ÷ëåíîì ñåìåéñòâà ñåðèí-òðåîíèíîâèõ ïðîòåèíôîñ-
ôàòàç, ïîñêîëüêó ñîäåðæèò ðåãóëÿòîðíûå òåòðàòðèêîïåïòèä-
íûå ïîâòîðû (TPR). PP5 àêòèâíî ó÷àñòâóåò â ïðîöåññàõ ñèãíàëü-
íîé òðàíñäóêöèè. Îïèñàíû ïðîöåäóðà ïîëó÷åíèÿ ìîíîêëîíàëüíûõ
àíòèòåë, ñïåöèôè÷íûõ ê PP5, à òàêæå îñîáåííîñòè èõ èñïîëüçî-
âàíèÿ â Âåñòåðí-áëîò àíàëèçå è èììóíîïðåöèïèòàöèè.Ìåòîäû.
Ãèáðèäîìíàÿ òåõíîëîãèÿ ïðèìåíåíà äëÿ ïîëó÷åíèÿ ìîíîêëîíàëü-
íûõ àíòèòåë. Èììóíèçàöèþ ïðîâîäèëè ðåêîìáèíàíòíûì ñëèòûì
áåëêîìGST-òàã, ñèíòåçèðîâàííûì â áàêòåðèàëüíîé ñèñòåìå. Ðå-
çóëüòàòû. Ïîëó÷åíû ñïåöèôè÷åñêèå ìîíîêëîíàëüíûå àíòèòåëà
ïðîòèâ ÐÐ5. Âûâîäû. Ìîíîêëîíàëüíûå àíòèòåëà ñïåöèôè÷íî
ðàñïîçíàþò ðåêîìáèíàíòíóþ è ýíäîãåííóþ PP5 â Âåñòåðí-áëîò
àíàëèçå è èììóíîïðåöèïèòàöèè. Îíè ìîãóò ñòàòü íåîáõîäèìûì
èíñòðóìåíòîì ïðè èññëåäîâàíèè ôèçèîëîãè÷åñêîé ðîëè PP5.
Êëþ÷åâûå ñëîâà: ïðîòåèíôîñôàòàçà 5, ãèáðèäîìíàÿ òåõíî-
ëîãèÿ, ìîíîêëîíàëüíûå àíòèòåëà.
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